Drs. Kim Abson and Laura Swanson, dermatologists at The Polyclinic Madison Center, are currently conducting a national research study investigating a topical foam product for the treatment of rosacea.
If you have rosacea, you are not alone. An estimated 16 million Americans have rosacea, a chronic and potentially life-disruptive disorder primarily of the facial skin. Although the signs and symptoms of rosacea can vary from one individual to another, in most cases it begins after age 30 as a redness on the cheeks, nose, chin or forehead. In some cases, rosacea may also occur on the neck, chest, scalp or ears. During inflammatory episodes, affected areas of the skin develop swelling, papules and pustules.
Why is the study being done?
Topical treatments facilitate easy application and even distribution of a medication. However, current approved topical treatments for rosacea rarely show sufficient clinical efficacy or provide only cosmetic relief for several hours. The topical foam product being investigated contains an antibiotic that is currently approved for oral use in the treatment of rosacea. The purpose of this study is to determine the product’s efficacy and safety.
Who is eligible to participate in the study?
To be eligible for the study patients must be 18 years or older with moderate-to-severe facial rosacea. Participants will receive study-related medical care at no cost. Reimbursement for completed study visits may also be provided.
For additional information about the study, please contact the study coordinator at email@example.com or (206)-320-6766.